Search results for "biliary"

showing 10 items of 238 documents

IgG Subclass Distribution of Autoantibodies to Glomerular Basement Membrane in Goodpasture’s Syndrome Compared to Other Autoantibodies

1988

The IgG subclass distribution of autoantibodies to glomerular basement membrane (anti-GBM antibodies) was investigated and compared to the distribution of liver-kidney microsomal (LKM) autoantibodies in chronic active hepatitis, to antimitochondrial autoantibodies (AMA) in primary biliary cirrhosis, and to the subclass distribution of total serum IgG within a healthy population. Solid phase assays for the demonstration of these autoantibodies were performed with four mouse monoclonal antibodies specific for each human subclass to provide quantitative data for the autoantibodies. In addition, the subclass distribution of total IgG in these sera was analyzed. IgG1 accounted for 75% of the tot…

Anti-Glomerular Basement Membrane DiseaseRenal glomerulusmedicine.drug_classKidney GlomerulusPopulationMitochondria LiverMonoclonal antibodyBasement MembraneSubclassmedicineHumansGoodpasture syndromeeducationAutoantibodiesHepatitis Chroniceducation.field_of_studybiologyLiver Cirrhosis Biliarybusiness.industryGlomerular basement membraneAutoantibodymedicine.diseasemedicine.anatomical_structureImmunoglobulin GImmunologyMicrosomes Liverbiology.proteinAntibodybusinessNephron
researchProduct

Transmission of hepatitis B and hepatitis delta viruses in the households of chronic hepatitis B surface antigen carriers: A regression analysis of i…

1991

Abstract To evaluate whether clinical and laboratory features of a hepatitis B surface antigen (HBsAg) carrier can predict risks of infection, its chronicity, and the development of liver disease among close contacts, the authors studied a cohort of 994 first degree relatives or cohabitants (household contacts) of 226 non-drug-addicted chronic HBsAg carriers (index cases), of whom 77% had liver disease and 26% were superinfected by hepatitis D virus (HDV). A logistic form of regression analysis was used to assess the role of each feature in the index case as predictor of hepatitis B virus (HBV)- and HDV-related outcomes among household contacts. Six models of risk, expressed as odds ratios,…

AdultMaleRiskHepatitis B virusHBsAgAdolescentEpidemiologymedicine.disease_causeLiver diseaseHumansMedicineHepatitis AntibodiesChildIndex caseAgedFamily HealthHepatitis B virusHepatitis B Surface Antigensbusiness.industryHepatobiliary diseaseInfantvirus diseasesMiddle AgedHepatitis BHepatitis Bmedicine.diseaseHepatitis Ddigestive system diseasesItalyHBeAgChild PreschoolCarrier StateDNA ViralMutationImmunologyRegression AnalysisFemaleHepatitis D virusHepatitis Delta Virusbusiness
researchProduct

LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arte…

2019

OBJECTIVE. The purpose of this study was to determine the diagnostic performance of hepatobiliary phase hypointensity and Liver Imaging Reporting and Data System (LI-RADS) major imaging features in the diagnosis of hepatocellular carcinoma (HCC) in hepatic lesions with arterial phase hyperenhancement (APHE) measuring 10-19 mm in patients at high risk of HCC. MATERIALS AND METHODS. A composite reference standard of pathologic analysis and imaging follow-up was used. The diagnostic performance (sensitivity and specificity) of hepatobiliary phase hypointensity and LI-RADS major imaging features other than APHE for the diagnosis of HCC was assessed and compared by means of a logistic regression…

AdultGadolinium DTPAMaleGadoxetic acidCirrhosisCarcinoma HepatocellularContrast MediaspecificityliverSensitivity and Specificity030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineHumansRadiology Nuclear Medicine and imagingIn patientLiver imagingAgedRetrospective StudiesAged 80 and overbusiness.industryLiver NeoplasmsMean ageGeneral Medicinehepatocellular carcinomaMiddle Agedmedicine.diseasesensitivityMagnetic Resonance Imaginggadoxetate disodiumgadoxetic acid030220 oncology & carcinogenesisHepatocellular carcinomaHepatobiliary phaseFemaleNuclear medicinebusinessArterial phasemedicine.drugMRIcirrhosi
researchProduct

Heterozygosity for the hemochromatosis gene in liver diseases - prevalence and effects on liver histology

2000

:Background/Aims: The effect of heterozygosity for the C282Y mutation in the HFE hemochromatosis gene on iron accumulation and disease progression in liver disease patients is unclear. Methods: We investigated the prevalence of this mutation in 531 patients and 205 healthy controls. In addition, we assessed the influence of the mutation on liver histology in 34 C282Y heterozygous and 124 age-, sex- and disease-matched controls without the mutation using the modified HAI and Chevallier score. Results: The highest prevalence of the C282Y mutation was observed in patients with autoimmune hepatitis (17.2%, p<0.01) compared to 6.4% in healthy controls. Heterozygotes with hepatitis C and B virus …

Hepatitismedicine.medical_specialtyHepatologybusiness.industryAutoimmune hepatitisHepatitis CHepatitis BCompound heterozygositymedicine.diseaseGastroenterologyLiver diseasePrimary biliary cirrhosisInternal medicineImmunologymedicinebusinessHemochromatosisLiver
researchProduct

The microbiota of the bilio-pancreatic system: A cohort, STROBE-compliant study

2019

Paola Di Carlo,1 Nicola Serra,2 Francesco D&rsquo;Arpa,3 Antonino Agrusa,3 Gaspare Gulotta,3 Teresa Fasciana,1 Vito Rodolico,1 Anna Giammanco,1 Consolato Sergi4,51Department of Sciences for Health Promotion, Mother &amp; Child Care, University of Palermo, Palermo, Italy; 2Statistic Unit, Department of Public Health, University of Naples &lsquo;Federico II&rsquo;, Naples, Italy; 3Department of General Surgery and Emergency, University of Palermo, Palermo, Italy; 4Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; 5Department of Laboratory Medicine and Pathology, Stollery Children&rsquo;s Hospital, University of Alberta, Edmonton, AB, CanadaBackgroun…

Human bile microorganismPancreatic and biliary tract diseaseSettore MED/18 - Chirurgia GeneraleSettore MED/07 - Microbiologia E Microbiologia ClinicaSurvivalSettore MED/17 - Malattie InfettiveE. colilcsh:RC109-216Human Bile microorganismslcsh:Infectious and parasitic diseases
researchProduct

Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

2022

Background: Comprehensive and contemporary data pertaining large populations of patients with Primary Biliary Cholangitis (PBC) and hepatocellular carcinoma (HCC) are missing. Aim: To describe main characteristics and outcome of PBC patients with HCC diagnosed in the new millennium. Methods: Analysing the Italian Liver Cancer registry we identified 80 PBC patients with HCC diagnosed after the year 2000, and described their clinical characteristics, access to treatment and survival. Results: Median age of patients was 71 years and 50.0% were males. Cirrhosis was present in 86.3% of patients, being well-compensated in 58.0%. Median HCC diameter was smaller in patients under surveillance (2.6 …

MaleCarcinoma HepatocellularCholestatic liver disease; Outcome; Surveillance; Survival; TreatmentSurveillanceHepatologySurvivalPrognosiLiver Cirrhosis BiliaryRisk FactorSettore MED/12 - GASTROENTEROLOGIALiver NeoplasmsGastroenterologyCholestatic liver diseasePrognosisTreatmentRisk FactorsHumansFemaleTreatment.HumanAgedOutcome
researchProduct

Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis.

1996

Abstract Background/Aims: Autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis are chronic liver diseases with probable autoimmune background. Overlapping features have been described for primary biliary cirrhosis and autoimmune hepatitis. In contrast, there have been only a few case reports on an overlap of autoimmune hepatitis and primary sclerosing cholangitis. Methods: We describe three male patients with clinical and histological overlapping features of primary sclerosing cholangitis and autoimmune hepatitis. Results: All initially asymptomatic patients had elevated levels of aminotransferases, alkaline phosphatase, γ-glutamyltranspeptidase and IgG. Anti-n…

AdultMalePathologymedicine.medical_specialtyCirrhosisAdolescentBiopsyCholangitis SclerosingAutoimmune hepatitisGastroenterologyPrimary sclerosing cholangitisAutoimmune DiseasesDiagnosis DifferentialPrimary biliary cirrhosisInternal medicinemedicineHumansTransaminasesHepatitis ChronicHepatitisAutoimmune diseaseCholangiopancreatography Endoscopic RetrogradeHepatologyBile ductbusiness.industryOverlap syndromeSyndromemedicine.diseasemedicine.anatomical_structureAntibodies AntinuclearImmunoglobulin GbusinessImmunosuppressive AgentsFollow-Up StudiesJournal of hepatology
researchProduct

Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

2022

Background &amp; Aims Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non-response in cirrhotic patients undergoing OCA therapy. Methods Safety and efficacy of treatment were evaluated in a cohort of consecutive PBC cirrhotic patients started with OCA. OCA response was evaluated according to the Poise criteria. Risk factors for hepatic SAEs and non-response were reported as risk ratios (RR) with 95% confidence intervals (CIs). Results One hundred PBC cirrhotics were included, 97…

Liver CirrhosisMaleliver decompensationsafetyHepatologyLiver Cirrhosis Biliarydecision curve analysis; efficacy; liver decompensation; safety; total bilirubin; Albumins; Ascites; Bilirubin; Chenodeoxycholic Acid; Humans; Liver Cirrhosis; Male; Liver Cirrhosis BiliaryBiliaryefficacyAscitesBilirubinChenodeoxycholic Acidtotal bilirubindecision curve analysiSettore MED/12AlbuminsHumansdecision curve analysis
researchProduct

PRIMARY BILIARY CIRRHOSIS AND CŒLIAC DISEASE

1978

medicine.medical_specialtyPrimary biliary cirrhosisbusiness.industryInternal medicinemedicineGeneral MedicineDiseasemedicine.diseasebusinessGastroenterologyThe Lancet
researchProduct

Anti-fibrotic therapy: lost in translation?

2012

While preclinical development of potential anti-fibrotics is far advanced, with numerous pharmacological targets and promising agents, almost none has entered clinical validation. Reasons are manifold, including the usually slow progression of liver fibrosis, requiring high numbers of well-stratified patients undergoing long-term treatment when conventional liver biopsy based parameters or hard liver-related endpoints are used. Importantly, there is a notorious lack of sensitive and specific surrogate markers or imaging technologies for liver fibrosis progression or regression that would permit a rapid clinical screening for potential anti-fibrotics. Nonetheless, in view of an urgent need f…

Liver Cirrhosismedicine.medical_specialtyCirrhosisPlacebo-controlled studyAutoimmune hepatitisChronic liver diseaseGastroenterologyPrimary sclerosing cholangitisTranslational Research BiomedicalPrimary biliary cirrhosisFibrosisInternal medicinemedicineAnimalsHumansIntensive care medicineHepatologymedicine.diagnostic_testbusiness.industryPatient Selectionmedicine.diseaseMagnetic Resonance ImagingDisease Models AnimalLiver biopsybusinessBiomarkersJournal of hepatology
researchProduct